Haemorheological effects of losartan and enalapril in patients with renal parenchymal disease and hypertension

Journal of Human Hypertension

Volumn 14, Issue 5, 2000, Pages 305-309

  Shand, B I ^a  

^a CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Angiotensin II antagonists; Angiotensin converting enzyme inhibitors; Erythrocyte deformability; Haemorheology; Plasma viscosity; Renal disease

Indexed keywords

CREATININE; ENALAPRIL; FIBRINOGEN; LOSARTAN;

ADULT; AGED; ARTICLE; BLOOD RHEOLOGY; CATION TRANSPORT; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG EFFECT; DRUG MECHANISM; ERYTHROCYTE DEFORMABILITY; FEMALE; FIBRINOGEN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY DISEASE; MALE; PLASMA VISCOSITY; RANDOMIZED CONTROLLED TRIAL;

EID: 0034070865     PISSN: 09509240     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jhh.1001011     Document Type: Article

References (30)

1. Letcher RL et al. Direct relationship between blood pressure and blood viscosity in normal and hypertensive subjects. Am J Med 1981; 70: 1195-1202.
2. Zannad F, Stoltz J-F. Blood rheology in arterial hypertension. J Hypertens 1992; 10 (Suppl 10): S69-S78.
3. Zannad F et al. Effects of lisinopril and hydrochlorothiazide on platelet function and blood rheology in essential hypertension: a randomly allocated doubleblind study. J Hypertens 1993; 11: 559-564.
4. Gomi T, Ikeda T, Ikegami F. Beneficial effect of α-blocker on hemorheology in patients with essential hypertension. Am J Hypertens 1997; 10: 886-892.
5. Boogaerts MA et al. Effect of beta-blocking drugs on red cell adhesive and rheological properties. J Lab Clin Med 1983; 102: 899-908.
6. Slonim A, Paran E, Cristal N. Effect of isradapine on factors affecting blood viscosity. Am J Hypertens 1991; 4: 172S-174S.
7. Ernst E, Bergmann H. Influence of cilazapril on blood rheology in healthy subjects. Am J Med 1989; 87 (Suppl 6B): 70S-71S.
8. Shand BI, Bailey RR, Lynn KL, Robson RA. Effect of enalapril on hemorheology in hypertensive patients with renal disease. Clin and Exp Hypertens 1995; 17: 689-700.
9. Goa KL, Wagstaff AJ. Losartan potassium. A review of its pharmacology, clinical efficacy and tolerability in the management of hypertension. Drugs 1996; 51: 820-845.
10. Moan A et al Effects of losartan on insulin sensitivity in severe hypertension: connections through sympathetic nervous system activity. J Hum Hypertens 1995; 9 (Suppl 5): S45-S50
11. Shand BI, Gilchrist NL, Nicholls MG, Bailey RR. Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study. J Hum Hypertens 1995; 9: 233-235.
12. Shand BI, Bailey RR, Simpson LO. Blood rheology in IgA nephropathy. Clin Nephrol 1988; 29: 288-293.
13. Gault MH, Longerich LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine. Nephron 1992; 62: 249-256.
14. International Committee for Standardization in Haematology (Expert panel on blood rheology). Guidelines for measurement of blood viscosity and erythrocyte deformability. Clin Hemorheol 1986; 6: 439-453.
15. Harkness J. The viscosity of human blood plasma; its measurement in health and disease. Biorheology 1971; 8: 171-193.
16. Millar HR, Simpson JG, Stalker AL. An evaluation of the heat precipitation method for plasma fibrinogen estimation. J Clin Path 1971; 24: 827-830.
17. Matrai A, Whittington RB, Ernst E. A simple method of estimating whole blood viscosity at standardized hematocrit. Clin Hemorheol 1987; 7: 261-265.
18. -]-cotransport function and dysfunction in different forms of primary hypertension. Am J Hypertens 1988; 1: 60S-63S.
19. David-Dufilho M et al. Control of the erythrocyte free Ca2+ concentration in essential hypertension. Hypertension 1992; 19: 167-174.
20. Touyz RM, Milne FJ. Alterations in intracellular cations and cell membrane ATPase activity in patients with malignant hypertension. J Hypertens 1995; 13: 867-874.
21. Malini PL, Strocchi E, Ambrosioni E, Magnani B. Long-term antihypertensive, metabolic and cellular effects of enalapril. J Hypertens 1984; 2 (Suppl 2): S101-S105,
22. Fujito K et al. Acute effects of angiotensin-converting enzyme inhibitor on erythrocyte sodium ion transport in essential hypertension. Life Sci 1992; 51: 2079-2087.
23. de la Sierra A et al. Effect of long-term antihypertensive therapy with angiotensin converting enzyme inhibitors on red cell sodium transport. Am J Hypertens 1995; 8: 622-625.
24. Golik A et al. Erythrocyte Na+, K+, and Ca2+, Mg(2+)-ATPase activities in hypertensives on angiotensin-converting enzyme inhibitors. Clin Biochem 1996; 29: 249-254,
25. Sanchez RA et al. Recovery of erythrocyte Na(+)-K(+]-Cl-cotransport activity by enalapril. Hypertension 1991; 17: 334-339.
26. Stuart J, Ellory JC. Rheological consequences of erythrocyte dehydration. Br J Haematol 1988; 69: 1-4.
27. Chopra M et al. Antioxidant effects of angiotensin-converting enzyme (ACE) inhibitors: free radical and oxidant scavenging are sulfhydryl dependent, but lipid peroxidation is inhibited by both sulfhydryl- and nonsulfhydryl-containing ACE inhibitors. J Cardiovasc Pharmacol 1992; 19: 330-340.
28. Aruoma OL. Characterisation of drugs as antioxidant prophylactics. Free Radical Biol Med 1996; 20: 675-705.
29. Lowe GDO. Blood rheology in vitro and in vivo. Bailliere's Clin Haematol 1987; 1: 597-636.
30. Shand BI, Bailey RR, Simpson LO. Blood rheology in IgA nephropathy. Clin Nephrol 1988; 29: 288-293.